ABBV Stock Navigator

Price Action & Technicals

• Recent Declines: ABBV closed at 198.71 on Apr 24, 2026, down 2.24%, and slipped 1.75% weekly to 204.72.
• 🔥 Oversold...

• Price underperformance: Closed at $206.23 (-1.01%), lagging S&P 500's -0.28% drop.
• Recent slide: -8.91% vs Medical sector's -7.53%.
• Earnings in...

UBS and Goldman Sachs upgrade AbbVie, forecasting 2026Q1 revenue at $16.9B and $1.08 EPS fueled by Humira's immunology strength. Bullish signal for traders eyeing rebounds and long-term growth.

Key historical insights for traders ahead of Q1 2026 earnings:

• 50% win rate: Shares rose immediately after 6 of 12 prior reports
• Slight downside...

• Narrow Q4 2025 EPS beat drives slight daily share dip amid full-year adjusted EPS of $10.00 (down 1.2%).
• 2026 guidance cut to $13.96-$14.16...

• Close (Apr 24, 2026): $198.71, down 1.11% (-$2.24)
• Day Range: $197.14 - $200.25
• Volume: 7.6M (108% vs 65-day avg 7.03M)
• 52-Wk Range: $176.57 - $244.81
  Key levels for Monday open; watch $197 support.

• Pricing Pressure: ABBV agreed to a major Humira discount via government-run TrumpRx platform.
• Offset Potential: Company weighs this against...

Strategic manufacturing push: Largest single-site investment ever at $1.4B on 185 acres in Durham, NC—US Center of Excellence for sterile injectables...

Key deal highlights:

• AbbVie licenses multiple preclinical to Phase 1 pain compounds from China's Haisco in up to $715M pact – its first foray into...

Key impacts for ABBV traders:

• Short-term pressure: Shares down in Friday premarket; YTD plunge of 12% vs. industry -5.3%.
• Manufacturing-only CRL:...

• Consensus PT $256 (range $190-$344), implying 28.9% upside from $199 amid YTD -10% dip—attractive entry for traders.
• Fresh bulls: Canaccord Buy...

Key update for ABBV traders:

• Completed Phase 1 study of ABBV-722 tablet in healthy adults, assessing body absorption and food effects to guide...

ABBV trend: Recent pullback signals buying opportunity amid oversold RSI near $205.

• Weekly slip: Down 1.75% to $204.72, under short-term...

Strong late-breaking data at SGO 2026 boosts AbbVie's oncology pipeline:

• 62.7% confirmed ORR (FRα ≥50% subgroup) with Elahere + carboplatin, median...

Nxera Pharma secures the third milestone from AbbVie in their neurology collaboration, advancing AbbVie's pipeline via key partner progress.

Key Wall Street estimates signal solid growth for AbbVie's Q1:

• EPS: $2.69, +9.4% YoY
• Revenue: $14.78B, +10.8% YoY
• Consensus EPS down 0.7% in...

• FDA issued CRL to AbbVie for trenibotulinumtoxinE BLA, delaying entry into competitive neurotoxin market.
• No safety/efficacy issues, but...

Key bearish signals for active traders:

• Rising trend broken: Medium-term channel floor breached, signaling weaker rise ahead.
• Rectangle sell...

Institutional buy signal: HB Wealth Management LLC raised its ABBV position by 6.7% in Q4. Accumulation like this often fuels short-term upside for active traders.

Hey there, welcome! I'm ABBV Stock Navigator, your dedicated guide to all things AbbVie Inc. ($ABBV), crafted just for active traders like you. I've...